Citat:
Som tur är för det är detta du dör av i de flesta fall. Jag trodde alla hade tagit till sig det faktum att de med svåra symptom av COVID19, där handlar det om att deras immunförsvar "misständer" och inte fungerar som det ska. Det är märkligt att nu ens diskutera detta. Vad det sedan beror på är en annan sak. Den här studien går igenom flera orsaker och bland annat tar man upp detta som en möjlig orsak:Antibody-dependent enhancementDet lustiga är att de sedan tar upp konvalescentplasma som en möjlig behandling hos de med immunopatologiska reaktioner:
The Antibody-dependent enhancement (ADE) of virus infection is a phenomenon in which preexisting sub-neutralizing antibodies enhance virus entry and replication, and has been observed for various viruses, including the Ebola and Dengue viruses.54,55 A neutralizing monoclonal antibody targeting the receptor-binding domain of the S protein of Middle East respiratory syndrome (MERS) virus has been shown to enhance virus entry into cells via the Fc portion of the antibody bound to the Fc receptor (FcR) on cells.43 This supports the relationship between antibody upregulation and poor outcome of patients with COVID-19. Nevertheless, the ADE-mediated inflammatory response and association of pre-existing antibodies with disease progression and severity in COVID-19 require further investigation.
Potential immunotherapeutic strategies for COVID-19
/.../
Convalescent plasma therapy
Convalescent plasma from patients that have recovered from a viral infection can be used as therapy for patients with COVID-19 without severe adverse events. One possible explanation for the efficacy of convalescent plasma therapy is that the antibodies present in convalescent plasma may inhibit viremia.65 Indeed, several studies have shown lower mortality rates for patients treated with convalescent plasma than those who did not receive this therapy.66,67,68 However, Cheng et al. demonstrated that it is more effective to administer convalescent plasma during early stages of the disease.66 However, despite potentially rapid availability, the deployment of convalescent plasma will be limited because transfusions are typically performed in hospital settings and may require large infusion volumes. In addition, there are adverse events for plasma transfusions, including mild fever, allergic reactions, life-threatening bronchospasm, transfusion-related acute lung injury, and circulatory overload in patients with cardiorespiratory disorders, which must be carefully tracked.69
https://www.nature.com/articles/s41392-020-00243-2
Så hela ditt resonemang blir obegripligt när du hävdar effektiviteten med konvalescensplasma samtidigt som du hävdar frånvaron av immunopatologiska reaktioner.
Vi kan sedan diskutera vad det beror på och ADE som möjlig eller omöjlig förklaring. Jag hävdar att man inte vet varför och att ADE är med som en hypotes i de vetenskapliga resonemangen.